Aimmune Therapeutics, the pharmaceutical company in late stage trial with it’s AR101 peanut oral immunotherapy (OIT) drug, announced a collaboration with Regeneron Pharmaceuticals and Sanofi.
The company will test its therapy in combination with Regeneron and Sanofi’s Dupixent in a mid-stage trial expected to start in 2018. Dupixent (the brand name for dupilumab) is an approved atopic dermatitis (eczema) drug in Phase II trials as a therapy for eosinophilic esophagitis (EoE).
The three companies plan the midstage test for 2018 with Regeneron sponsoring the trial. The primary objective is to exceed the tolerated dose of peanut protein in a double-blind, placebo-controlled food challenge than that attained by AR101 alone.
Aimmune is currently conducting two Phase III trials of AR101.